WAT

Waters Corporation (WAT) - Q2 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended June 28, 2025. Waters Corporation is a global leader in analytical instruments and software, primarily serving life sciences, materials, and food sciences through its Waters and TA Instruments segments. The company designs, manufactures, and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and mass spectrometry (MS) systems.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 9% in Q2 and 7% year-to-date (YTD), driven by strong demand across most geographies. Instrument system sales grew 5% in Q2, while recurring revenues (consumables and services) grew 12% in Q2.
• Geographic Performance: Sales in China increased 17% in Q2, attributed to customers pulling forward chemistry consumable purchases ahead of new tariffs. U.S. sales declined 1% in Q2, while Europe grew 14%.
• Operating Income: Q2 operating income was flat (-0.5%) despite revenue growth, impacted by a change in sales mix, merit increases, and approximately $14 million in transaction costs related to the BD merger. YTD operating income increased 5%, aided by the absence of $10 million in litigation provisions recorded in the prior year.
• Acquisitions: The company acquired Halo Labs for $35 million in May 2025. Results are included from the acquisition date but were immaterial to consolidated results.
• Debt Reduction: Total debt decreased to $1.46 billion from $1.63 billion at year-end 2024, with net debt borrowings decreasing by $170 million YTD.

Guidance, Outlook, and Risks

• Major Transaction: On July 13, 2025, Waters entered into a definitive agreement to acquire Becton, Dickinson & Company's (BD) Biosciences & Diagnostic Solutions business in a Reverse Morris Trust transaction valued at approximately $17.5 billion. The deal is expected to close in Q1 2026. Waters will assume approximately $4 billion of incremental debt.
• Transaction Costs: The company incurred $14 million in transaction-related expenses through June 28, 2025, and estimates total expenses and financing fees of approximately $120 million upon closing.
• Tariff Risks: The company faces potential impacts from new U.S. tariffs on imported goods. Management notes that approximately $8 million of China chemistry sales in Q2 may have been pulled forward due to these tariffs.
• ERP Implementation: The company is implementing a new worldwide ERP system, with anticipated total spending of $130 million over three years. $7 million of operating costs were incurred YTD 2025.
• Tax Legislation: The company is evaluating the impact of the "One Big Beautiful Tax Bill Act" enacted on July 4, 2025, which adjusts U.S. corporate income tax rates.

Investor Verification Checklist

• Merger Closing Conditions: Verify the status of regulatory approvals and shareholder votes required for the $17.5 billion BD acquisition.
• Tariff Impact: Assess the sustainability of Q2 China sales growth and the potential for demand normalization in Q3/Q4 2025.
• Debt Capacity: Review the company's ability to service the additional ~$4 billion in debt associated with the BD merger alongside existing obligations.
• ERP Execution: Monitor the progress and cost overruns of the $130 million ERP implementation.
• Share Repurchases: Note that the company has $1.0 billion remaining in its share repurchase authorization but has not made open market repurchases in 2025.